Quinolones are an important class of heterocyclic compounds that possess interesting biological activities like antimicrobial, antitubercular, and antitumor. The objective of this study is to evaluate in silico the antitumoral and antimycobacterial activity of some quinolone derivatives by using CLC Drug Discovery Workbench Software. Docking studies were carried out for all ligands, and the docking scores were compared with the scores of standard drugs, topotecan and levofloxacin. The docking studies have been carried out to predict the most possible type of interaction, the binding affinities, and the orientations of the docked ligands at the active site of the target protein.
Introduction
In medical practice, many quinolone derivatives with antimicrobial activity are used; some of these being considered by pharmacists as the primary drugs in human and veterinary anti-infectious therapy. Quinolones have a broad spectrum and a strong antibacterial activity [1, 2] . They are characterized by pharmacokinetics that allows their use in all localized infections. Recently, pharmacological studies have shown that quinolones also possess other biological activities: antitumor activity [3] [4] [5] [6] , antimycobaterial activity [7] , antiviral activity on herpes virus, inhibiting neurovegetative diseases and ischemic infections, and food product storage (due to bactericidal properties). First antitumoral quinolone is Voreloxin: (+)-1,4-dihydro-7-(3S4S)-3-hydroxy-4-amino-1-pyrrolidinyl-4-oxo-1-(2-thiazolyl)-1.8-naphthyridine-3-carboxylic acid (Figure 1 ) [3] . Some quinolone derivatives (e.g., Moxifloxacin: 1-cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydro-1H-pyrrolo [3,4-b] pyridin-6(2H)yl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid- Figure 2) show activity against Mycobacterium tuberculosis, and these compounds are the first new antimycobacterial drugs to be available since the discovery of rifampin [8] .
Lascufloxacin (AM-1977) ( Figure 3) [9, 10] is a new 8-methoxy fluoroquinolone antibacterial agent with unique pharmacophores at the first and seventh positions of the quinolone rings. The oral and parenteral formulations have been developed for the treatment of community-acquired pneumonia and other respiratory tract infections in Japan. Lascufloxacin shows in vitro activity against various respiratory pathogens, such as Staphylococcus aureus, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae, and Mycoplasma pneumoniae.
Quinolones, considered to be "privileged building blocks," are obtained through simple and flexible synthesis methods and allow design and development of large libraries of bioactive molecules. A 2011 study on 21 antibiotics launched since 2000 has highlighted that the discovery and development of new antibiotics obtained through chemical synthesis is still topical. Of the nine antibiotics obtained by chemical synthesis, launched between 2000 and 2011, eight antibiotics belong to the class of fluoroquinolones [11] . New drugs introduced into medical therapies each year are privileged structures for specific biological targets. These new chemical entities provide a perspective on molecular recognition, serving as a basis for designing future new drugs. In 2016, 19 chemically synthesized drugs were approved [12] , with the two drugs having the quinolone structure: nemonoxacin ( Figure 4 ) and zabofloxacin ( Figure 5 ). The objective of this study is to evaluate "in silico" antitumoral and antimycobacterial activities of some quinolone derivatives by using CLC Drug Discovery Workbench Software [13] . Docking studies were conducted for all ligands, and the docking scores were compared with the scores of standard drugs, topotecan and levofloxacin.
Materials and methods

Structure and the synthesis pathway of the quinolone derivatives
In previous papers, we presented the synthesis of quinolone derivatives with antimicrobial activity [1, 2] . The results have revealed that the compounds represented in Figure 6 have showed weak antibacterial activities against the tested strains. For this reason, we have initiated in silico drug design and molecular docking studies to predict anticancer and antitubercular activities targeting DNAtopoisomerase I and topoisomerase IV from Klebsiella pneumoniae, respectively.
We have performed molecular docking studies to see how the nature of substituents on the quinolone ring influences the anticancer and antitubercular activities targeting human DNA topoisomerase I and topoisomerase IV from Klebsiella pneumoniae, respectively. The studies have been realized with CLC Drug Discovery Workbench Software [13] in order to achieve accurate predictions on optimized conformations for both the quinolones (as ligands) and their target receptor proteins to form stable complexes.
The quinolone compounds have been synthesized by Gould-Jacobs cyclization process (Scheme 1). Appropriate unsubstituted aniline (1) is reacted with diethyl ethoxymethylenemalonate (DEEMM) to produce the anilinomethylene malonate derivatives (2) . A subsequent thermal process induces Gould-Jacobs cyclization to afford the corresponding 4-hydroxy-quinoline-3-carboxylate ethyl ester (3). The following operation is the alkylation/arylation of the quinolone compound (4), which is usually accomplished by reaction with allyl chloride, benzyl chloride, or para fluoronitrobenzene to produce the qinolone-3-carboxylate ester (4)(R 1 = allyl, benzyl, para nitrophenyl) [14-16, 19, 20] . The qinolone-3-carboxylate ester (4) (R 1 = isopropyl) was obtained by the reaction of the corresponding monosubstituted aniline (5)(R 1 = isopropyl) (the aniline (5) was obtained by reductive amination of acetone with sodium borohydride-acetic acid [14] [15] [16] 19] or triacetoxyborohydride [17, 18] ) with DEEMM. A strong acid (such as polyphosphoric acid) is often needed to induce cyclization directly resulting in the formation of N-isopropyl-4-oxoquinolone-3-carboxylate ester (4)(R 1 = isopropyl).
The final manipulation is the basic or acid hydrolysis that cleave the ester generating the biologically active free carboxylic acid (7)(R 1 = allyl, isopropyl, benzyl, para nitrophenyl). The displacement of 7-chloro group from the biologically active free carboxylic acid (7) with 4-methyl-piperidine yielded the compound (8) (R 1 = allyl, benzyl, isopropyl, para nitrophenyl) ( Table 1 ). The quinolone compounds (8)(R 1 = para amino phenyl) ( Table 1 ) have been synthesized by a common reduction of nitro group using sodium dithionite [20] .
Ligand preparation
To achieve the docking studies, the quinolone derivatives (ligands) must be prepared to be imported in the molecular docking project. The ligands (Table 1) Figure 6 . General structure of the investigated quinolone compounds, where R 1 = allyl, isopropyl, benzyl, p-nitro-phenyl, p-amino-phenyl and R 6 = F, Cl, H, CH 3 .
The synthesis of the quinolone compound using Gould-Jacobs cyclization process. [20] E: À1341.39572 au have been prepared using SPARTAN'14 software package [21] according to the protocol described in our previous work [22] . The DFT/B3LYP/6-31 G * level of basis set has been used for the computation of molecular structure, vibrational frequencies, and energies of optimized structures. Some chemical properties, highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) energy values, HOMO and LUMO orbital coefficient distribution, molecular dipole moment, polar surface area (PSA) (a descriptor that has been shown to correlate well with passive molecular transport through membranes, therefore, allows the prediction of transport properties of the drugs), the ovality, polarizability (useful to predict the interactions between nonpolar atoms or groups and other electrically charged species, such as ions and polar molecules having a strong dipole moment), and the octanol water partition coefficient (log P) have been calculated ( Table 2 ).
Docking studies
The docking protocol was performed according to the CLC Drug Discovery Workbench Software and was described in a previous paper [22] . The docking scores and hydrogen bonds formed with the amino acids from group interaction atoms were used to predict the binding modes, the binding affinities, and the orientation of the docked quinolone derivatives in the active site of the target proteins.
Docking evaluation against human DNA topoisomerase
Docking studies have been carried out in order to achieve accurate predictions on the optimized conformations for both the quinolone derivatives (as ligands) and
Quinolone derivatives 2D structures 3D optimized structures [20] E: À1281.47987 au E = energy and au = atomic units. protein target to form a stable complex. All of the investigated compounds have been docked on the crystal structure of human DNA topoisomerase I (PDB ID: 1K4T) [23] . Binding site and docking pose of the co-crystallized topotecan (TTC), interacting with amino acid residues of the active site, are shown in Figure 7a . The TTC was taken as reference ligand to compare the docking results of quinolone derivatives. The docking score, the interacting group, and hydrogen bonds formed with the group interaction atoms of the corresponding amino acids are shown in Table 3 . Interactions of quinolone derivatives PQ11 (score: À63.31 and RMSD: 0.12), 6ClPQ11 (score: À62.95 and RMSD: 0.08), HPQ11 (score: À62.77 and RMSD: 0.06), 6MePQ11(score: À62.48 and RMSD: 0.01), and 6MePQ13 (score: À61.22 and RMSD: 0.04) showed better docking score than that of co-crystalized TTC (score:
À59.15 and RMSD: 0.14) as shown in Figures 7b-10a . The most active compound, 6ClPQ11, was predicted to have a significant docking score (À63.31) and forms one hydrogen bond with GLU 418 (bond length À 2.961 Å) ( Figure 8a) . Docking poses of all quinolone derivatives in the ligand binding site of human DNA topoisomerase I are shown in Figure 10b .
Docking evaluation against topoisomerase IV from Klebsiella pneumoniae
Docking studies have been carried out in order to obtain optimized docking conformations of the investigated quinolone derivatives on the crystal structure of topoisomerase IV (PDB ID: 5EIX) from Klebsiella pneumoniae [24] . The binding site and docking pose of the co-crystallized levofloxacin (LFX) ligand, interacting with amino acid residues of the ligand binding site of topoisomerase IV from Klebsiella pneumoniae, are shown in Figure 11a . The levofloxacin was taken as reference ligand to compare the docking results of quinolone derivatives. The docking score, the interacting group, and hydrogen bonds formed with the group interaction atoms of the corresponding amino acids are shown in Table 4 . Interactions of quinolone derivatives PQ4 (score: À43.98 and RMSD: 0.05), 6ClPQ4 (score: À41.12 and RMSD: 0.25), PQ11 (score: À48.32 and RMSD: 0.10), HPQ11 (score: 49.57 and RMSD: 0.11), PQ12 (score: À42.76 and RMSD: 0.18), and APQ13 (score: À42.96 and RMSD: 0.32) showed better docking score than that of co-crystalized LFX (score: 37.26 and RMSD: 0.02) as shown in Figures 11b-14a . The most active compound, HPQ11, was predicted to have a significant docking score (À49.57) and forms one hydrogen bond with ASP95 (bond length À 3.081 Å) (Figure 13a) . Docking poses of all quinolone derivatives in the ligand binding site of topoisomerase IV from Klebsiella pneumoniae are shown in Figure 14b . Table 3 .
List of docking interactions between the ligand molecules and human DNA topoisomerase I using CLC Drug
Discovery Workbench Software. Important molecular properties of the investigated compounds, e.g., molecular weight, flexible bonds, the number of hydrogen bond donors, the number of hydrogen bond acceptors, and log P, have been calculated. These parameters can be used to evaluate whether a molecule has properties that would make it a likely orally active drug, according to the Lipinski's rule of five [22] . The number of violations of the Lipinski rules allows to evaluate drug likeness for a molecule ( Table 5 ).
Results and discussions
All of the investigated compounds have been docked on human DNA topoisomerase (PDB ID: 1K4T) and topoisomerase IV (PDB ID: 5EIX) from Klebsiella Table 4 .
List of docking interactions between the ligand molecules and topoisomerase IV (PDB ID: 5EIX) from
Klebsiella pneumoniae using CLC Drug Discovery Workbench Software. pneumoniae. In case of the molecular docking studies on the human DNA topoisomerase I, all the quinolone derivatives reveal docking scores greater than À50. Only five compounds, e.g., PQ11 (À63.31), 6ClPQ11 (À62.95), HPQ11 (À62.77), 6MePQ11 (À62.48), and 6MePQ13 (À61.22), reveal better docking scores than that of co-crystallized TTC (À59.15) ( Figure 15 ). In case of the molecular docking studies on topoisomerase IV from Klebsiella pneumoniae, only three quinolone derivatives, e.g., 6MePQ4 (À35.7), 6ClPQ12 (À35.34), and 6MePQ12 (À35.39), reveal docking scores less than that of levofloxacin (À37.26). The compounds that show better docking scores than that of levofloxacin are HPQ11 (À49.57), PQ11 (À48.32), PQ4 (À43.98), PQ12 (À42.76), APQ13 (À42.96), and 6ClPQ4 (À41.12) ( Figure 16 ). It was observed that the presence of the benzyl substituent in N-1 position of the 7(4-methyl-piperidinyl)-quinolones core leads to increased docking score against human DNA topoisomerase and topoisomerase IV from Klebsiella pneumoniae. The compounds PQ11, 6ClPQ11, HPQ11, and 6MePQ11 reveal better docking scores than that of the reference ligands, topotecan (TTC) and levofloxacin (LFX), docked on human DNA topoisomerase (PDB ID:1K4T) and topoisomerase IV (PDB ID: 5EIX) from Klebsiella pneumoniae, respectively. 
Conclusions
The virtual screening of the investigated compounds using docking has been carried out with CLC Drug Discovery Workbench Software and has led to the identification of quinolone derivatives for inhibiting the activities of topoisomerase I and topoisomerase IV. It was observed that the presence of the benzyl substituent in N1 position of the 7-(4-methyl-piperidinyl)-quinolones core leads to increased docking score against human DNA topoisomerase and topoisomerase IV from Klebsiella pneumoniae.
The compounds PQ11 (1-benzyl-6-fluoro-7-(4-methyl-piperidin-1-yl)-1,4dihydro-4-oxo-quinolin-3-carboxylic acid), 6ClPQ11 (1-benzyl-6-chloro-7-(4-methyl-piperidin-1-yl)-1,4-dihydro-4-oxo-quinolin-3-carboxylic acid), HPQ11 (1-benzyl-7-(4-methyl-piperidin-1-yl)-1,4-dihydro-4-oxo-quinolin-3-carboxylic acid), and 6MePQ11 (1-benzyl-6-methyl-7-(4-methyl-piperidin-1-yl)-1,4-dihydro-4-oxo-quinolin-3-carboxylic acid) reveal better docking scores than that of the reference ligands, topotecan (TTC) and levofloxacin (LFX), docked on human DNA topoisomerase (PDB ID: 1K4T) and topoisomerase IV (PDB ID: 5EIX) from Klebsiella pneumoniae, respectively.
